Efficacy and safety of losartan in hypertensive patients with side effects induced by other antihypertensive agents

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 11, 1997, Pages 851-858

  Giovannetti, Roberto ^a   Del Corso, Claudia ^a   Galeone, Francesco ^a   Giuntoli, Franco ^a   Saba, Paolo ^a  

^a Hospital of Val di Nievole   (Italy)

Author keywords

Angiotensin II; Antagonist; Antihypertensive drugs; Blood pressure; Losartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031406592     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80051-3     Document Type: Article

References (44)

1. Smith RD, Chiu AT, Wong PC, et al. Pharmacology of non-peptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
2. Griendling KK, Alexander RW. The angiotensin (AT1) receptor. Semin Nephrol. 1993; 13:558-566.
3. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications. J Hypertens. 1993;11(Suppl 3):S13-S18.
4. Mc Innes GT. Antihypertensive drugs: New developments and new agents. Curr Opin Cardiol. 1986;1:594-602.
5. Zanchetti A. Role of calcium-antagonists in systemic hypertension. Am J Cardiol. 1987; 59:130B-136B.
6. Sanders E. Re-evaluating stepped care for hypertension. Progr Ther. 1988;18:46-54.
7. Kostis JB. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am J Hypertens. 1989;2:57-64.
8. Waeber B, Nussberger J, Brunner HR. Angiotensin converting enzyme inhibitors in hypertension. In: Laragh JK, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1990:2209-2232.
9. Salvetti A. Newer ace inhibitors, a look at the future. Drugs. 1990;40:800-828.
10. Fagard R, Amery A, Reybrouk T, et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol. 1980;46:295-300.
11. Schwarz A. Calcium antagonists: Review and perspective on mechanism of action. Am J Cardiol. 1989;64:31-91.
12. Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ. 1986;293:471-474.
13. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
14. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet. 1990;335:1109-1113.
15. Cruickshank JM, Messerli FH, eds. Left Ventricular Hypertrophy and Its Regression. London: Science Press; 1992:33-34.
16. Holzegreve H, Burkle B. Anti-atherosclerotic effects of calcium antagonists. J Hypertens. 1993;11(Suppl 1):S55-S59.
17. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
18. Sasaki S, Arakawa K. Effect of captopril on serum lipids, lipoproteins and apolipoproteins in patients with mild essential hypertension. Curr Ther Res. 1986;40:898-901.
19. Giuntoli F, Galeone F, Gabbani S, et al. Antihypertensive and metabolic effects of nitrendipine in hypertensive diabetic patients. Clin Ther. 1990;12:421-425.
20. Giuntoli F, Galeone F, Natali A, et al. Antihypertensive and metabolic effect of nitrendipine in non insulin-dependent diabetes mellitus with hypertension. J Cardiovasc Pharmacol. 1992;19(Suppl 2):S39-S40.
21. Giuntoli F, Gabbani S, Natali A, et al. Effects of perindopril on carbohydrate and lipoprotein metabolism in essential hypertension. Am J Med. 1992;92(Suppl 4):95S-97S.
22. Lewis JG. Adverse reactions to calcium antagonists. Drugs. 1983;25:196-222.
23. Gustafsson D. Microvascular mechanisms involved in calcium antagonists oedema formation. J Cardiovasc Pharmacol. 1987;10(Suppl 1):S121-S131.
24. Di Bianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol. 1986;1:122-141.
25. Lacourciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: The design of a prospective, controlled study. J Hypertens. 1994;12(Suppl 2):S49-S53.
26. WHO Expert Committee. Arterial hypertension report of a WHO experts committee to clinical report series no 268, Geneva, 1978.
27. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Report 1984. Arch Intern Med. 1984;144:1045-1057.
28. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertens. 1995;13(Suppl 1):S77-S80.
29. Chan JCN. Randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium, compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens. 1995;9:765-771.
30. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345-1350.
31. Tikkanen I, Dmvik P, Jensen H. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995;13:1343-1351.
32. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995;155:405-411.
33. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a non peptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
34. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994;7:1041-1044.
35. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press. 1994;3(Suppl 5):185-188.
36. Ashino K, Goto HE, Sumita SI, et al. Efficacy of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension. Blood Press. 1994;3(Suppl 5):122-129.
37. Wong PC, Price WA Jr, Chiu AT, et al. In vivo pharmacology of DUP-753. Am J Hypertens. 1991;4(Suppl 2):S288-S298.
38. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardlovasc Pharmacol. 1993;22:579-584.
39. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DUP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333-335.
40. Gansevoort RT, De Zeeuw D, Shahinfar S, et al. Effects of angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens. 1994;12(Suppl 2):S37-S42.
41. Brunner HR, Delzcretaz E, Nussberger J, et al. Angiotensin II receptor antagonists DUP-753 and TCV-116. J Hypertens. 1994;12(Suppl 9):S29-S34.
42. Shaw W, Snavely D, Shahinfar S. Safety and efficacy of losartan (DUP-753, MK-954) in hypertensive patients with renal impairment. J Am Soc Nephrol. 1994;5:567. Abstract.
43. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DUP-753, a specific angiotensin II receptor antagonist, to normal male volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
44. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.